An interventional study of cloxacillin and heparin in Double Lumen Infection and Hemodialysis, sponsored by Shiraz University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-04-21.
Sponsored by Shiraz University of Medical Sciences · Not applicable, Interventional, and Prevention
The purpose of this study is to investigate whether cloxacillin lock is effective in prevention of double lumen infection.
Double lumen infection is one of the causes of morbidity and mortality in hemodialysis patients. Many strategies used to prevent it and one of them is antibiotic lock. Thus we select chronic hemodialysis patients and divided them into 2 groups. One group received cloxacillin and heparin as catheter lock and the second group received only heparin lock.
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 100 is below the median of 120 across 4,200 interventional studies indexed under Infections.
Browse Infections studies →Shiraz University of Medical Sciences is the lead sponsor of 129 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
cloxacillin 100 mg/ml + heparin 1000iu/ml as catheter lock at the end of hemodialysis
Drug: cloxacillin · Drug: heparin
heparin 1000iu/ml as catheter lock at the end of hemodialysis
Drug: heparin
cloxacillin 100mg/ml as catheter lock at the end of hemodialysis
heparin 1000iu/ml as catheter lock at the end of hemodialysis
catheter infection
Time frame: 6 months
This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shiraz University of Medical Sciences